Article
作者: Salituro, Gino ; MacLean, John ; Cooke, Andrew ; Ali, Amjad ; Stribling, Sloan ; Lassman, Mike ; Chen, Qing ; Clemas, Joe ; Belshaw, Simone ; Forrest, Gail ; Hajdu, Richard ; Szeto, Daphne ; McLaughlin, Theresa ; Kuethe, Jeff ; Gibson, Jack ; Pai, Lee-Yuh ; Liu, Kun ; Carswell, Emma ; Tung, Elaine ; London, Clare ; Verras, Andreas ; Buist, Nicole ; Park, Min K. ; Wisniewski, Tom ; Sok, Andrea ; Bopp, Charlene ; Struthers, Mary ; Castro-Perez, Jose ; Bennett, D. Jonathan ; Tang, Wei ; Robinson, John ; Rosenbach, Mark ; Hoyt, Scott B. ; Liang, Gui-Bai ; Cai, Jiaqiang ; Ma, Xiuying ; Xiong, Yusheng ; Metzger, Joe ; Tata, Jim ; Ren, Ning ; McMasters, Daniel ; Cai, Tian-Quan ; Clarkson, Thomas R. ; Zhou, Gaochao ; Rivera, Nelo ; Maxwell, Carrie Ann ; Brown, Lindsay ; Cully, Doris
We report the discovery of a benzimidazole series of CYP11B2 inhibitors. Hit-to-lead and lead optimization studies identified compounds such as 32, which displays potent CYP11B2 inhibition, high selectivity versus related CYP targets, and good pharmacokinetic properties in rat and rhesus. In a rhesus pharmacodynamic model, 32 produces dose-dependent aldosterone lowering efficacy, with no apparent effect on cortisol levels.